However, DNA methylation biomarkers could further improve disease prognosis, especially given their potential to be developed for liquid biopsy, such as the FDA approved Epi proColon test for colorectal cancer; based on PCR detection of methylated SEPT9 (septin 9) in cell‐free circulating DNA shed from tumours into the bloodstream.41 This evidence concerns the gene SEPTIN9 and colorectal cancer.